Elacridar | P-gp inhibitor | Probechem Biochemicals

Chemical Structure : Elacridar

CAS No.: 143664-11-3

Elacridar (GF-120918,GW-0918, GG-918)

Catalog No.: PC-45887Not For Human Use, Lab Use Only.

Elacridar (GF120918, GW-0918) is a potent inhibitor of multidrug resistance (MDR, P-gp) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.

Packing	Price	Stock
25 mg	$128	In stock
50 mg	$198	In stock
100 mg	$298	In stock
250 mg		Get quote

Get Quotation Now

* Please select Quantity before adding items.

or Bulk Inquiry

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Biological Activity

Elacridar (GF120918, GW-0918) is a potent inhibitor of multidrug resistance (MDR, P-gp) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
Elacridar (GF120918, GW-0918) effectively competes with [3H]azidopine for binding P-glycoprotein.
Elacridar (GF120918, GW-0918) restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.

Physicochemical Properties

M.Wt	563.6429
Formula	C34H33N3O5
Appearance	Solid
CAS No.
Storage	Solide Powder -20 °C 12 Months; 4°C 6 Months	In Solvent -80 °C 6 Months; -20°C 6 Months
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-

References

1. Hyafil F, et al. Cancer Res. 1993 Oct 1;53(19):4595-602.

2. den Ouden D, et al. Leukemia. 1996 Dec;10(12):1930-6.

3. Witherspoon SM, et al. Clin Cancer Res. 1996 Jan;2(1):7-12.

Elacridar (GF-120918,GW-0918, GG-918)

Biological Activity

Physicochemical Properties

References

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

Get Quote

* Indicates a Required FieldYour information is safe with us.